Cyclosporine use linked to 90.9% higher infection risk in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis patients

Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are severe, life-threatening cutaneous adverse drug reactions characterized by extensive epidermal detachment. These conditions carry high morbidity and mortality rates, often requiring intensive care and presenting significant challenges in management. Current standard-of-care primarily focuses on identifying and discontinuing the causative drug, alongside aggressive supportive care. However, specific pharmacological interventions beyond supportive measures remain a subject of ongoing research, with varying outcomes reported for immunomodulatory therapies. This study aims to characterize the clinical profile and treatment outcomes of SJS/TEN patients in a Latin American tertiary hospital setting.